Novo Holdings Leads Us$200M Series A Investment In Asia-Based Life Sciences Tools Company Esco Lifesciences Group

May 27, 2021•about 4 years ago

Amount Raised

$200 Million

Round Type

series a

Singapore

Description

Novo Holdings today announced that it has co-led with Vivo Capital the over-subscribed US$200 million Series A and Crossover round in Esco Lifesciences Group ("Esco"), a leading provider of life sciences tools and services. The financing will enable Esco to strengthen its position through organic and external growth and transformation, as well as invest in China, thus addressing some of the most dynamic market segments and geographies. Other investors include two Asian sovereign wealth funds and Singapore-based global investor, EDBI.

Company Information

Company

Esco Lifesciences Group

Location

Singapore, Southeast Asia, Singapore

About

Esco Lifesciences Group provides enabling technologies, products and services to the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing. Headquartered in Singapore, Esco has an extensive sales network in over 100 countries, direct sales and service offices in over 20 countries, 8 manufacturing and R&D hubs in the US, Europe, the UK, China, Singapore, Indonesia, and over 1600 employees worldwide. SOURCE Novo Holdings

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Novo Holdings Leads Us$200M Series A Investment In Asia-Based Life Sciences Tools Company Esco Lifesciences Group

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information